Cytosorbents Corporation cash flow to debt ratio of -42.52% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cytosorbents Corporation's free cash flow has increased -14.76% from $-14.71M last year to $-12.54M, signaling increasing performance

Cytosorbents Corporation's debt to equity ratio is 8.64, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Cytosorbents Corporation's debt has increased relative to shareholder equity from 2.42 last year to 8.64 today, signaling weakened financials

Cytosorbents Corporation has negative EBITDA, making leverage ratio unreliable

Cytosorbents Corporation's interest coverage ratio is -11.65, which means that the company struggles to meet interest obligations, signaling financial risk.

Cytosorbents Corporation's profit margin has increased (-45.28%) in the last year from -58.21% to -31.85%, signaling increasing performance

Cytosorbents Corporation's short-term assets of $20.63M exceed its short-term liabilities of $9.71M

Cytosorbents Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cytosorbents Corporation's return on equity of -165.13%, is lower than 15.00%, indicating bad performance

Cytosorbents Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cytosorbents Corporation had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Cytosorbents Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

Cytosorbents Corporation has negative free cash flow, indicating cash burn

Cytosorbents Corporation's yearly earnings has increased -60.43% since last year from $-20.72M to $-8.20M, signaling increasing performance

Cytosorbents Corporation's yearly revenue has increased 4.13% since last year from $35.59M to $37.06M, signaling increasing performance

ROIC -41.17% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cytosorbents Corporation's 3-year revenue CAGR of 2.23% is positive, indicating growing revenue over the past 3 years

Cytosorbents Corporation had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Cytosorbents Corporation had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Cytosorbents Corporation has insufficient data to evaluate this check.

Cytosorbents Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cytosorbents Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cytosorbents Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cytosorbents Corporation is overvalued relative to its fair value price of -2.27 based on Earnings Fair Value model

Cytosorbents Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cytosorbents Corporation has a price-to-book ratio of 11.10x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Cytosorbents Corporation has a price-to-sales ratio of 0.66x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue